Soligenix Inc. has announced the publication of positive results from its Phase 2a proof of concept study evaluating SGX945 (dusquetide) for the treatment of Behçet's Disease in the journal Rheumatology (Oxford). The study focused on patients with aphthous ulcers associated with Behçet's Disease. Results demonstrated that SGX945 treatment led to improvements in oral pain, reduced duration and number of oral ulcers, and was well-tolerated with no treatment-related adverse events reported. The improvements were sustained during a follow-up period after treatment had ended. Soligenix plans to pursue a reformulation of SGX945 to enable home-based subcutaneous administration and intends to engage regulatory authorities for the design of a follow-on clinical study.